Arkolith/Insider Trading/TEVA/Form 4

Fox Christine

EVP, U.S. CommercialTEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) · full profile →Form 4 · filed Mar 6, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$295K
Net Open-Market Flow
-$295K
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 4, 2026Option exercise(M)20K——84K
Mar 4, 2026Sell(S)9K$32.46$295K75K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 4, 2026Option exercise(M)20K—$041K
Mar 4, 2026Grant(A)51K—$051K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-096498) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML